Ravel Health

Ravel Health

Virtual consultations for Lyme patients

Claim My Business
Security Type
Female Founder, Healthcare/Medical, B2C, Subscription, Health & Fitness
Min Investment
Edgewater, CO
Expected Close Date
April 29, 2024
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Key Deal Facts

Lyme is 1.5x more common than breast cancer, 476K new cases/yr, 2 mil+ chronic cases, $1.3B+ mrkt/yr
Studies show chronic Lyme is associated w/a worse quality of life than most other chronic illnesses
Founded by chronic Lyme patients who've led successful companies, in collaboration with Lyme experts
250+ patients on waitlist w/no marketing spend; licensed docs vetted & pilot set to launch June 2023
Experienced CMO & Advisory Team; numerous partnerships with leading Lyme organizations
Legal & software development teams in place; partial platform built (remaining development at cost)
Ambassador program, influencer partnerships & already-requested podcast interviews ready to go
Plans to add other complex chronic illness, incl. Long Covid & mold in 2023

Management Team / Advisory Board Bios

Kevin Williams Co-FounderChronic Lyme patient, successful software development firm founder & tech entrepreneur who’s completed hundreds of digital projects, with tens of thousands of collective users, Jaime Intile Co-FounderChronic Lyme patient with decades of experience in
marketing & leadership development and a proven track record for building highly successful teams, Dr. Tom Moorcroft, DO Chief Medical Officer & Pilot LeadDr. Tom treats some of the sickest, most sensitive patients suffering from chronic Lyme disease, tick-borne co-infections, mold illness as well as children with infection-induced autoimmune encephalitis (PANS/PANDAS)., Dr. Darin Ingels, ND Advisory Team & Pilot LeadNaturopathic Doctor, author, international speaker & leading authority on Lyme, who overcame his own 3-year battle with the disease, Dr. Richard Horowitz, MD Advisory TeamBoard-certified internist with 30+ years of experience treating over 13,000 patients for Lyme & associated tick-borne disorders, author of 2 national best-selling books on Lyme Disease & consultant to various federal agencies, Timothy J. Sellati, Ph.D. Advisory TeamAs Chief Scientific Officer at Global Lyme Alliance (GLA), Dr. Sellati leads strategic planning and coordinates research initiatives to accelerate the development of more effective methods of diagnosis and treatment of Lyme & TBD., Lauren Lovejoy Advisory TeamFounder & President, Lyme Warrior: Tireless advocate & one of the most connected leaders in the space, working to empower those with Lyme disease while continuing her own healing journey, James Maskell Advisory TeamSerial healthcare founder, nationally renowned author & in-demand speaker, with one of the largest functional medicine followings in the world
Amount Raised : $74,950
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

A CAFES (Contract and Future Equity Stake) can convert into different types of equity upon a Triggering Event, such as: common or preferred stock for a corporation, limited partnership interest for a limited partnership and membership interest for a limited liability company. At the time of the Triggering Event, the specific rights and limitations associated with the equity stake being issued to the investors will be determined and disclosed by the Entrepreneur.

Research Reports

No reports have been submitted

Become a Reporter